New hope for tough blood cancers: first human trial of JNJ-95804306 begins
NCT ID NCT07572006
First seen May 11, 2026 · Last updated May 15, 2026 · Updated 2 times
Summary
This early-stage study tests a new drug called JNJ-95804306 in about 280 people with blood cancers (like leukemia) that have returned or not improved after standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. The study has two parts: first finding a safe dose, then testing that dose more broadly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.